ArticleJournal of child and adolescent psychopharmacology2018
Characteristics of Children Prescribed Antipsychotics: Analysis of Routinely Collected Data.
Article in Journal of child and adolescent psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 61 citations in OpenAlex.
- Neurological Adverse Effects of Antipsychotic Medication in Children and Young People.Paediatric drugs · 2026Review
- Review
- Guidelines and practice on antipsychotics prescribing and physical health monitoring in children and young people: a cohort study using primary care data.BMJ mental health · 2025Article
- Methods used to construct disability indicators in linked administrative datasets: a systematic scoping review.Population health metrics · 2025Article
- Growing evidence of pharmacotherapy effectiveness in managing attention-deficit/hyperactivity disorder in young children with or without autism spectrum disorder: a minireview.Frontiers in psychiatry · 2024Review
- Views on sharing mental health data for research purposes: qualitative analysis of interviews with people with mental illness.BMC medical ethics · 2023Article
- State of the Evidence for Use of Psychotropic Medications in School-Age Youth.Children (Basel, Switzerland) · 2023Review
- Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Serious Adverse Drug Reactions to Antipsychotics in Minors with Multiple Disabilities: Preventability and Potential Cost Savings by Therapeutic Drug Monitoring.Pharmacopsychiatry · 2023Article
- Article
- Article
- Nation-Wide Routinely Collected Health Datasets in China: A Scoping Review.Public health reviews · 2022Article
- Incidence, Mortality and Survival in Young People with Co-Occurring Mental Disorders and Substance Use: A Retrospective Linked Routine Data Study in Wales.Clinical epidemiology · 2022Article
- Amantadine for the treatment of childhood and adolescent psychiatric symptoms.Proceedings (Baylor University. Medical Center) · 2021Article
- Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study.Children (Basel, Switzerland) · 2021Article
- Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case-control study in Korea.European child & adolescent psychiatry · 2021Article
- On the Causal Interpretation of Rate-Change Methods: The Prior Event Rate Ratio and Rate Difference.American journal of epidemiology · 2021Article
- Impact of schizophrenia genetic liability on the association between schizophrenia and physical illness: data-linkage study.BJPsych open · 2020Article
- Utility of oxcarbazepine in the treatment of childhood and adolescent psychiatric symptoms.Proceedings (Baylor University. Medical Center) · 2020Article
- Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies.Neuropharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveAntipsychotics are licensed for psychosis and are also prescribed for behavior control. This study aims to examine characteristics and outcomes of children prescribed antipsychotics.
methodsA cohort study using general practice and hospital records linked with education records for 1,488,936 children living in Wales between 1999 and 2015. The characteristics of the children who were prescribed antipsychotics are presented using descriptive statistics and outcomes such as respiratory illness, diabetes, and injury were analyzed using multilevel logistic regression and the prior event rate ratio (PERR).
resultsChildren with intellectual difficulty/autism were more likely to be prescribed antipsychotics (2.8% have been prescribed an antipsychotic [75% with autism] compared with 0.15% of children without intellectual difficulty). Those with intellectual disabilities/autism were prescribed antipsychotics at a younger age and for a longer period. Antipsychotic use was associated with a higher rate of respiratory illness for all (PERR of hospital admission: 1.55 [95% CI: 1.51-1.598] or increase in rate of 2 per 100 per year in those treated), and for those with intellectual difficulty/autism, there was a higher rate of injury and hospitalized depression. However, among those without intellectual difficulty/autism, there were lower rates of depression (PERR: 0.55 [95% CI: 0.51-0.59]).
conclusionsThis work shows real-world use of antipsychotics and provides information on the rate of possible adverse events in children treated. Antipsychotics are predominantly used for those with intellectual difficulty/autism rather than those with a psychotic diagnosis. There is evidence that rates of respiratory disease, epilepsy, and diabetes are also higher postantipsychotic use for all. In those with intellectual difficulty/autism, hospital-admitted depression and injury are higher postantipsychotic use. The use of antipsychotics for behavioral management is likely to have increased cost implications to the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.